Polycystin-1 inhibits eIF2α phosphorylation and cell apoptosis through a PKR-eIF2α pathway. by Tang, Yan et al.
1ScieNTific RepoRts | 7: 11493  | DOI:10.1038/s41598-017-11526-0
www.nature.com/scientificreports
Polycystin-1 inhibits eIF2α 
phosphorylation and cell apoptosis 
through a PKR-eIF2α pathway
Yan Tang1, Zuocheng Wang2, JungWoo Yang2, Wang Zheng2, Di Chen2, Guanqing Wu3,4, 
Richard Sandford5, Jingfeng Tang6 & Xing-Zhen Chen2,6
Autosomal dominant polycystic kidney disease (ADPKD) is caused by mutations in PKD1 or PKD2 
which encodes polycystin-1 (PC1) and polycystin-2, respectively. PC1 was previously shown to slow 
cell proliferation and inhibit apoptosis but the underlying mechanisms remain elusive or controversial. 
Here we showed in cultured mammalian cells and Pkd1 knockout mouse kidney epithelial cells that 
PC1 and its truncation mutant comprising the last five transmembrane segments and the intracellular 
C-terminus (PC1-5TMC) down-regulate the phosphorylation of protein kinase R (PKR) and its substrate 
eukaryotic translation initiation factor 2 alpha (eIF2α). PKR is known to be activated by interferons and 
dsRNAs, inhibits protein synthesis and induces apoptosis. By co-immunoprecipitation experiments 
we found that PC1 truncation mutants associate with PKR, or with PKR and its activator PACT. Further 
experiments showed that PC1 and PC1-5TMC reduce phosphorylation of eIF2α through inhibiting 
PKR phosphorylation. Our TUNEL experiments using tunicamycin, an apoptosis inducer, and GADD34, 
an inhibitor of eIF2α phosphorylation, demonstrated that PC1-5TMC inhibits apoptosis of HEK293T 
cells in a PKR-eIF2α-dependent manner, with concurrent up- and down-regulation of Bcl-2 and Bax, 
respectively, revealed by Western blotting. Involvement of PC1-regulated eIF2α phosphorylation and 
a PKR-eIF2α pathway in cell apoptosis may be an important part of the mechanism underlying ADPKD 
pathogenesis.
Autosomal dominant polycystic kidney disease (ADPKD) occurs with an incidence of ~1:1000 in all ethnic 
groups and develops as the result of mutations in the PKD1 (~70–85%) or PKD2 (~15–30%) gene, which encodes 
the protein product polycystin-1 (PC1) or polycystin-2 (PC2), respectively1. PC1 is a large 11-transmembrane 
protein containing an extracellular domain with Ig repeats and a short cytoplasmic domain that interacts with 
numerous signaling molecules2, 3. It is localized in cilia and at sites of cell-matrix and cell-cell interactions4. 
Animal models revealed that both loss- and gain-of-function of PC1 are cystogenic5. ADPKD is associated with 
dysregulated epithelial cell proliferation and apoptosis as well as elevated expression of oncogenes c-Myc and Bcl-
26, 7. Expression of PC1 in Madin-Darby canine kidney (MDCK) cells was reported to result in tubule formation 
and resistance to apoptosis8. PC1-inhibited apoptosis was linked to the phosphatidylinositol 3-kinase (PI3K)/
Akt- and Gα12/Jun N-terminal kinases (JNKs)-dependent pathways9, 10. Interestingly, it was found that G protein 
α12 (Gα12) is necessary for the cystogenesis induced by dysregulated PC1 because lack of Gα12 in mice abol-
ished PC1-dependent cyst formation11. Despite the tremendous progress made during the past two decades, the 
molecular mechanisms underlying ADPKD pathogenesis remain controversial.
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Protein kinase R (PKR) was first identified in early 1990’s12, 13 but its existence in interferon (IFN)-treated 
vaccinia virus-infected L cells and its double-stranded RNA (dsRNA)-dependent kinase activity were known 
many years earlier14, 15. PKR is a 551-amino-acid (aa), 68-kDa ubiquitously expressed serine/threonine kinase 
composed of a catalytic C-terminus and a regulatory dsRNA-binding N-terminus containing two dsRNA-binding 
motifs16. It is also a pivotal antiviral protein and an essential component of the innate immunity that acts early in 
host defence prior to the onset of IFN counteraction and acquired immune responses17. Other than dsRNAs from 
cellular, viral or synthetic origins, PKR can be activated by Toll-like receptors, growth receptors and cytokines 
such as interleukin-1 and tumor necrosis factor α, and a variety of cellular stress inducers such as arsenite, thapsi-
gargin and H2O218. Further, the PKR-activating protein (PACT), which is activated by viral or non-viral stimuli, 
acts as a mediator that links a wide range of stress conditions to PKR activation19. Following binding of dsR-
NAs, PKR undergoes dimerization and auto-phosphorylation, and then phosphorylates its substrates, including 
eukaryotic translation initiation factor 2 alpha (eIF2α), protein phosphatase 2 A (PP2A) and IκB kinase (IKK). 
Through these substrates and downstream effectors PKR regulates translation, transcription and apoptosis18, 20. 
In addition to PKR, eIF2α is phosphorylated by three other kinases corresponding to different stress conditions: 
endoplasmic reticulum (ER) stress-activated protein kinase-like ER kinase (PERK), nutrient restriction-activated 
general control nonderepressible 2 (GCN2), and heme-regulated inhibitor (HRI)21.
Once activated by cellular stress, PKR inhibits proliferation and initiates apoptosis through phosphorylation 
of eIF2α to inhibit new protein synthesis, inhibition of B-cell lymphoma 2 (Bcl-2) function and activation of 
signaling pathways including nuclear factor (NF)-κB, p53, and signal transducer and activator of transcription 
122, 23. In addition, in response to stress conditions, increased phosphorylated eIF2α (P-eIF2α) up-regulates, both 
directly and through activating transcription factor 4 (ATF4), downstream effectors such as
homocysteine-induced ER protein (Herp) and C/EBP-homologous protein (CHOP)21, 24, 25. Apoptotic cell 
death is also ensued by ATF4-CHOP- mediated induction of several pro-apoptotic genes and by reduced syn-
thesis of anti-apoptotic Bcl-2 proteins26. Likewise, the apoptosis induction by PKR involves phosphorylation of 
eIF2α, thereby regulating the expression of different genes such as pro-apoptotic Fas, Bcl-2-like protein-4 (Bax) 
and p5327–29. Interestingly, Bcl-2 was shown to block PKR-induced apoptosis30, 31. PKR-expressing cells contained 
elevated Bax and low levels of Bcl-2, while in cells expressing a catalytically inactive PKR variant, Bax was ablated 
and Bcl-2 was elevated29. Further, it was recently reported that the PKR/PP2A signaling axis is required for rapid 
and potent stress-induced apoptosis32.
To date, there has been no report about the relationship between PC1 and PKR involving apoptosis. In the 
present study, we employed cultured cell lines to investigate a PKR-dependent downstream pathway that is 
involved in mediating the effect of PC1 on apoptosis.
Results
Effects of PC1 on PKR and eIF2α phosphorylation in cultured cell lines and mouse kid-
neys. We have previously reported that PC2 represses cell proliferation through promoting the P-eIF2α by 
kinase PERK33. Here we tested whether PC1 is involved in the regulation of eIF2α or its kinases. WB experiments 
using HEK293T cells revealed that expression of PC1-5TMC (aa 3,895–4,302), a truncation mutant of PC1 com-
prising of the last five transmembrane (TM) segments and the intracellular C-terminus (PC1C, aa 4,104-4,302), 
which contains the 20-amino acid (amino acids 4,134–4,153) fragment known to bind and activate G proteins34 
(Fig. 1A), results in a decrease in the phosphorylated PKR (P-PKR) and P-eIF2α (Fig. 1B). In average, PC1-
5TMC decreased the P-eIF2α/eIF2α ratio by 63.4% ± 7.7% (p = 0.001, N = 15) and P-PKR/PKR by 84.4% ± 9.1% 
(p = 0.001, N = 10) (Fig. 1C). Similar effects of PC1-5TMC were observed in HeLa cells (Fig. 1D). Furthermore, 
HEK cells stably expressing Flag-tagged mouse wild-type (WT) PC1 exhibited similar effects as PC1-5TMC on 
P-eIF2α and P-PKR (Fig. 1E and F). To determine whether PC1 has similar effects under more in vivo conditions, 
we also utilized primary epithelial cells prepared from Pkd1−/− knockout (KO) mouse embryonic kidneys for 
similar WB experiments. We found that the P-PKR/PKR and P-eIF2α/eIF2α ratios are increased in the Pkd1−/− 
cells as compared with control (Pkd1 +/+) cells similarly prepared from WT kidneys (Fig. 1G and H). These data 
together showed that PC1 down-regulates P-PKR and P-eIF2α in cultured cell lines and mouse kidneys.
Interaction of PC1 with PKR and PACT. We next examined whether there exists a physical interac-
tion between PC1 and PKR. For this we performed co-immunoprecipitation (co-IP) experiments in HEK cells 
over-expressing PC1C or PC1-5TMC. We found that indeed PC1C and PC1-5TMC are able to precipitate PKR 
(Fig. 2A and B), suggesting that PC1 is in the same complex as PKR in HEK cells. Because the PKR activator PACT 
is known to bind with PKR35, we also immunoprecipitated with a PACT antibody and indeed found the PC1C, PKR 
and PACT signals in the precipitate, with reduced PKR band intensity in the presence of PC1C (Fig. 2C), suggesting 
that PC1C reduces the PKR-PACT interaction strength, possibly through competing with PACT for binding PKR.
Down-regulation of P-PKR by the membrane-anchored PC1 C-terminus. To determine which part 
of PC1 is required for the reduction of the P-PKR level, we transfected human PC1-5TMC, PC1-1TMC and PC1C 
into HEK293T cells, and found by WB assays that while PC1-1TMC (aa 4084-4302) (Fig. 1A) has a similar inhib-
itory effect on P-PKR as PC1-5TMC, PC1C does show any significant effect (Fig. 3A). Using cell surface biotiny-
lation assays we found that green fluorescent protein (GFP)-tagged PC1-1TMC and -5TMC, but not GFP alone, 
traffic to the plasma membrane (PM) of HeLa cells (Fig. 3B). These data together suggest that the PM-anchored 
PC1 C-terminus but not the PC1 C-terminus alone confers the down-regulation of the PKR activity.
Dependence of the down-regulation of P-eIF2α by PC1 on the kinase activity of PKR. We 
next examined whether PC1-mediated down-regulation of P-eIF2α involves the activity of the eIF2α kinase 
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PKR, using IFN-α to activate PKR. We first found that PC1-5TMC abolishes the up-regulation of P-PKR and 
P-eIF2α by the inducer (Fig. 4A). We then transfected HEK cells with PKR and dominant negative PKR mutant 
K296R that retains the auto-phosphorylation ability but has no kinase activity36. As expected, while the PKR 
over-expression increased both the P-eIF2α and P-PKR level, over-expression of mutant K296R has no effect on 
eIF2α phosphorylation (Fig. 4B, left panel), confirming that mutant K296R has no kinase activity. Consistently, 
we found that PC1-5TMC inhibits the phosphorylation of both the WT and mutant PKR (Fig. 4B, right panel). 
Consequently, PC1-5TMC substantially reduced the P-eIF2α level in cells over-expressing PKR but had no sig-
nificant effect on P-eIF2α in those over-expressing mutant K296R (Fig. 4B, right panel). We found that full-length 
PC1 and PC1-5TMC in general have similar effects on the P-eIF2α level (Fig. 4C). Taken together, our data sug-
gest that PC1 inhibits PKR phosphorylation through which it down-regulates the eIF2α activity.
We next utilized PKR knockdown by siRNA to further document the down-regulation of P-eIF2α through 
inhibiting PKR phosphorylation. By using and comparing HEK293T cells with and without stable expression of 
Flag-tagged full-length PC1, we found that either PKR knockdown or mutant K296R over-expression abolishes 
the down-regulation of P-eIF2α by WT PC1 (Fig. 4C). These data are in general in support of our conclusion 
that PC1 represses eIF2α phosphorylation through down-regulating PKR kinase activity. We noticed that PKR 
knockdown has little effect on eIF2α phosphorylation (Fig. 4C), suggesting the possibility that the basal levels of 
P-eIF2α be mainly attributed to a protein phosphatase or an eIF2α kinase other than PKR.
Figure 1. Down-regulation of P-eIF2α and P-PKR by PC1. (A) Schematic presentation of human PC1 
membrane topology, showing 11 transmembrane domains, extracellular N- and intracellular C-termini. 
The numbers and positions of the starting amino acids for three truncation mutants are indicated. (B) 
Representative WB data. 60 µg of total proteins from HEK293T cells transfected with PC1-5TMC or GFP vector 
were loaded for immunoblotting. Blots were probed with the indicated antibodies. β-actin served as loading 
controls. Control (Ctrl), GFP vector; 5TMC, GFP-tagged PC1-5TMC. (C) Statistical data showing the relative 
activities (%) of eIF2α and PKR in HEK293T cells from panel B assessed by P-eIF2α/eIF2α and P-PKR/PKR, 
respectively. Shown are averaged P-eIF2α/eIF2α (N = 15, P = 0.002, paired t-test) and P-PKR/PKR (N = 10, 
P = 0.001, paired t-test). (D) Representative WB data using HeLa cells from similar experiments as in panel 
B. (E) Representative WB data using native HEK293T cells and those stably expressing mouse WT PC1. Cell 
were collected and loaded for immunoblotting by the indicated antibodies. Ctrl, native HEK293T cells; PC1, 
HEK293T cells stably expressing Flag-tagged full-length PC1. (F) Statistical data showing averaged ratios (%) 
of P-eIF2α/eIF2α (N = 9, P = 0.007, paired t-test) and P-PKR/PKR (N = 10, P = 0.002, paired t-test) from panel 
E. (G) Representative WB data showing the expression of P-eIF2α and P-PKR in mouse Pkd1 knockout mouse 
embryonic kidney epithelial cells. +/+, WT; −/−, Pkd1 homozygote. (H) Averaged and normalized ratios (%) 
of P-eIF2α/eIF2 and P-PKR/PKR from panel G are plotted. *p = 0.04, **p = 0.002 (N = 4, paired t-test).
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Figure 2. Interaction between PC1 truncation mutants, PKR and PACT by co-IP. (A) Representative data 
showing interaction between PC1C and PKR in HEK293T cells transiently transfected with pEGFP-PC1C or 
pEGFP. Total proteins from the transfected HEK293T cells were precipitated with anti-GFP (EU4), followed 
by SDS-PAGE and WB assays with anti-GFP (B-2). The blots were stripped and reprobed with the antibody 
against human PKR. Ctrl, GFP vector; PC1C, GFP-tagged PC1 C-terminus. (B) Representative data showing 
interaction between PC1-5TMC and PKR in HEK293T cells transiently transfected with pEGFP-PC1-5TMC or 
pEGFP. Experimental conditions were similar to those described in panel A. (C) Representative data showing 
interaction of PC1C with endogenous PKR and PACT in HEK293T cells. Total proteins from HEK293T cells 
were precipitated with anti-PACT antibody and detected with anti-GFP and anti-PKR antibodies.
Figure 3. Effects of different PC1 domains on reducing the levels of P-PKR and P-eIF2α. (A) Representative 
data obtained using HEK293T cells transiently transfected with PC1-5TMC, PC1-1TMC, PC1C or GFP 
vector. Cell lysates were prepared for immunoblotting with the indicated antibodies. β-actin served as loading 
controls. 5TMC, GFP-tagged PC1-5TMC; 1TMC, GFP-PC1-1TMC; PC1C, GFP-tagged PC1 C-terminus. (B) 
Representative data obtained from surface biotinylation assays using HeLa cells transiently transfected with 
GFP-tagged PC1-5TMC or PC1-1TMC or GFP vector (control). Cells were incubated with 1 mg/ml Pierce EZ-
LinkTM Sulfo-NHS-SS-Biotin. The biotinylated and flow-through intracellular proteins were separated using 
100 µl of Pierce Avidin Agarose. An equal amount of biotinylated proteins and 20 µg of total and intracellular 
proteins were separated on 8% SDS-PAGE for immunoblotting.
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Dependence of PC1-inhibited apoptosis on a PKR-eIF2α pathway. Because PC1 and PKR were 
respectively known to inhibit and induce cell apoptosis8, 9, 18, 37, we wondered whether PC1 inhibits apoptosis 
through down-regulating the PKR and eIF2α activities. For this purpose we carried out TUNEL assays to deter-
mine apoptosis of HEK293T cells after transfection of PC1-5TMC and Western blot (WB) assays to evaluate the 
P-eIF2α/eIF2α or P-PKR/PKR ratios, in the presence and absence of tunicamycin (Tm) as an apoptosis inducer38.
Our WB data showed that PC1-5TMC suppresses P-PKR and P-eIF2α, with or without Tm treatment, while 
Tm increases the P-eIF2α level (Fig. 5A). TUNEL assays revealed that PC1-5TMC significantly represses apoptosis 
in the absence (P = 0.003) and presence of Tm treatment (P < 0.001) (Fig. 5B and C). Tm significantly increased 
the percentage of apoptotic cells (P < 0.001) (Fig. 5C), consistent with previous reports that P-eIF2α induces apop-
tosis20, 21, 24. To provide further documentations, we over-expressed growth arrest and DNA damage-inducible pro-
tein 34 (GADD34), a negative regulator of P-eIF2α, in HEK293T cells to promote lower level of P-eIF2α by protein 
phosphatase 1 (PP1). Indeed, while eIF2α phosphorylation and apoptosis were both repressed by GADD34, the 
inhibitory effect of PC1-5TMC on apoptosis was also abolished (Fig. 5D and E). Thus, these data together strongly 
indicated that a P-eIF2α pathway mediates the inhibition of cell apoptosis by PC1-5TMC.
Figure 4. Dependence of the PC1-regulated eIF2α activity on P-PKR kinase activity. (A) Effect of IFNα. 
Representative data showing the effects of PC1-5TMC on the activity of PKR and eIF2α in the presence and 
absence of IFNα in HEK293T cells that were transfected with GFP-tagged PC1-5TMC or GFP vector and 
treated with IFNα at 1,000 U/ml for 24 hours. Blots were probed with the indicated antibodies. (B) Left panel: 
Effects of the PKR K296R mutation on the PKR and eIF2α activity. HEK293T cells transfected with WT PKR, 
PKR-K296R or GFP vector. Right panel: Roles of the PKR K296R mutation on the regulation of the PKR and 
eIF2α activity by PC1 truncation mutant. HEK293T cells transfected with PC1-5TMC or GFP vector were 
co-transfected with WT PKR or PKR-K296R. Blots were then probed with the indicated antibodies. Ctrl, GFP 
vector; PKR, WT PKR; K296R, PKR-K296R. (C) Roles of PKR expression and kinase activity on regulation of 
the PKR and eIF2α activity by PC1. Native HEK293T cells and those stably expressing WT PC1 were transiently 
transfected with WT PKR, PKR-K296R or PKR siRNA before blots were probed with the indicated antibodies. 
For P-eIF2α blots in the presence of PKR over-expression, bands obtained with a shorter exposure time 
(0.5 min, vs regular exposure of 2 min) was also shown to avoid band saturation.
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We next sought to identify proteins implicated in the anti-apoptotic function of PC1. PKR were previously 
shown to activate Bax and inactivate Bcl-228–31. The inhibitory effect of WT PC1 on cell apoptosis was also sup-
ported by our WB finding in HEK293T cells that it enhances the level of Bcl-2 while reducing the level of Bcl-
2-like protein-4, Bax, presumably through inhibiting the PKR and eIF2α activities (Fig. 6A), which are in line 
with previous studies28–31. In average, WT PC1 increased the level of Bcl-2 by 43.9% ± 10.6% (p = 0.005, N = 5) 
and reduced that of Bax by 30.4% ± 12.5% (p = 0.01, N = 5) (Fig. 6B). These results are in support of the assump-
tion that PC1 inhibits apoptosis through down-regulating P-PKR/P-eIF2α.
Discussion
In this study we have shown that PC1 promotes lower levels of P-PKR and P-eIF2α using cultured cell lines and 
Pkd1−/− mouse embryonic kidney cells. In the presence of dominant negative PKR mutant K296R that loses the 
kinase activity, PC1 and PC1-5TMC did no longer exhibit any inhibitory effect on eIF2α phosphorylation, strongly 
indicating that PC1 down-regulates P-eIF2α through repressing the PKR activity. Previous studies have shown that 
PC1 is involved in regulation of de-phosphorylation through forming a holoenzyme complex with PP1 alpha (PP1α) 
via a conserved PP1α-binding motif within the polycystin-1 C-terminus, through it regulates downstream signal-
ing39. For example, PC1 promotes lower level of PC2 at Ser829 through recruitment of PP1α40. It was also known that 
GADD34 functions as a scaffold to reduce the level of P-eIF2α by interacting with both PP1α and eIF2α41.
Figure 5. Dependence of PC1-inhibited apoptosis on P-eIF2α/P-PKR. (A) Effects of PC1 and Tm treatment 
on P-eIF2α and P-PKR. HEK293T cells were transfected with GFP-tagged PC1-5TMC (5TMC) or GFP (Ctrl) 
and treated with Tm (2.5 µM in 5% dimethyl sulphoxide (DMSO)) or DMSO (5%, as control) at 24 hours 
post-transfection. After 24 hours, cell lysates were loaded for immunoblotting. HSP60 served as a loading 
control. (B) Photomicrographs of HEK293T cells used for TUNEL assays (magnification × 200). HEK293T 
cells were transfected with PC1-5TMC or GFP vector before being treated with DMSO or Tm and performed 
as in Fig. 5A. TUNEL-positive cells were indicated by circles. (C) Statistical data from TUNEL assays similarly 
performed as in panel B and averaged to compare apoptotic levels in HEK293T cells treated with Tm or DMSO 
(Ctrl) before the experiments. Apoptosis was assessed as the percentage of apoptotic/total cell numbers. 8–20 
pictures per treatment were randomly taken for analysis. 100-300 cells per picture were analyzed. N = 26–43 
pictures, *p < 0.05, **p < 0.01, ***p < 0.001. (D) HEK293T cells were transfected with PC1-5TMC or GFP 
vector and 24 hours later transfected with GADD34 or empty vector (Ctrl). After 24 hours, TUNEL assays 
were similarly performed as in panel B. Statistical data were from the TUNEL assays and averaged to compare 
the apoptotic levels in the above treated HEK cells. Apoptosis indicates the percentage of apoptotic/total cell 
numbers. N = 26–41, **p < 0.01. (E) Representative data obtained from the same conditions as in panel D and 
showing the effects of GADD34 and PC1-5TMC on P-eIF2α.
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While we found in this study that PC1 and PC1-5TMC down-regulate P-eIF2α through repressing PKR 
kinase activity, our previous study found that PC2 promotes eIF2α phosphorylation through enhancing the effi-
ciency of PERK as a kinase in phosphorylating eIF2α33. On the other hand, besides the involvement of PC1 in 
regulating apoptosis8, 9, both PC1 and PC2 are known to be anti-proliferative33, 42. Thus, the inhibition of cell pro-
liferation by PC1 should be through a pathway independent of the PKR-eIF2α axis because regulation through 
this axis would lead to increased proliferation. Future experiments will explore whether and how PC1 regulates 
proliferation through a PKR-mTOR axis.
We noticed that in the presence of PKR knockdown by siRNA or over-expression of dominant negative mutant 
K296R PC1 does not further reduce the P-eIF2α level (Fig. 4C). We think that this is because under this condition 
the P-eIF2α level must be defined by other eIF2α kinases and phosphatases and thus be insensitive to PC1.
PC1 is known to induce resistance to apoptosis through PI3K/Akt and Gα12/JNK pathways9, 10 while the catalytic 
activity of PKR is known to promote phosphorylation of the PI3K pathway components such as Akt/protein kinase 
B (PKB), ribosomal protein S6 and eukaryotic initiation factor 4E binding protein 1 (4E-BP1). Reversely, induction 
of PI3K signaling antagonizes the pro-apoptotic and anti-synthesis effects of conditionally activated PKR43. Further, 
NF-κB as a downstream effector of PI3K/Akt was also shown to be involved in PC1-regulated apoptosis. For exam-
ple, NF-κB inhibitor parthenolide reduced the anti-apoptotic effect of the PC1 cytoplasmic terminus44. On the other 
hand, it was found that PKR chronologically activates cell survival through NF-κB and cell death through eIF2α 
phosphorylation45. Therefore, how the PKR-eIF2α pathway is engaged in cross-talk with the PI3K/Akt and other 
signaling pathways with respect to regulation of cell apoptosis by PC1 is subject to future studies. In summary, our 
data were in support that PC1 inhibits cell apoptosis through a pathway that depends on the P-PKR/P-eIF2α axis 
and its downstream factors, anti-apoptotic Bcl-2 and pro-apoptotic BAX. Further studies should examine which 
apoptosis pathway downstream of P-eIF2α that is implicated in mediating the anti-apoptotic effect of PC1.
Materials and Methods
Antibodies and reagents. Rabbit antibodies against Phospho-eIF2α (Ser51), eIF2α, PKR were purchased 
from Cell Signaling Technology (New England Biolabs, Pickering, ON). Phospho-PKR (pT446), P-PKR (Thr 
446), PKR (B-10), PACT, Bcl-2, Bax antibodies were from Epitomics (Burlingame, CA) or Santa Cruz (Santa 
Cruz, CA). Affinity purified goat polyclonal anti-GFP (EU4) (Eusera, Edmonton, AB) was utilized for immu-
noprecipitation and mouse monoclonal anti-GFP (B-2) (Santa Cruz) for immunoblotting using GFP-tagged 
plasmids. Rabbit (A2066, Sigma-Aldrich Canada, Oakville, ON) or mouse anti-β-actin (C4, Santa Cruz), goat 
anti-FLAG (Santa Cruz) and mouse monoclonal anti-HSP60 (H-1) (Santa Cruz) antibodies were used for loading 
controls. Secondary antibodies were purchased from GE Healthcare (Baie d’Urfe, Quebec) or Santa Cruz. Tm and 
IFN-α were from Sigma-Aldrich Canada.
Cell culture, DNA constructs and transfection. HEK293T and HeLa cells were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with L-glutamine, penicillin-streptomycin, and 10% fetal 
bovine serum at 37 °C and 5% CO2. HEK293T cells stably expressing Flag-tagged full length mouse PC1 was 
a generous gift of Dr. J. Yang (Columbia University, NY) and cultured under above-described medium supple-
mented with 2 µg/ml of puromycin (Sigma-Aldrich Canada)46. pcDNA3 plasmids encoding the N-terminal 
GFP-tagged PC1 C-terminus (PC1C, aa 4104-4302), last 5 TMs plus PC1C (PC1-5TMC, aa 3895–4302), and 
last TM plus PC1C (PC1-1TMC, aa 4084–4302) were constructed by site-directed mutagenesis using Stratagene 
QuikChange® II XL Site-Directed Mutagenesis Kit (Agilent Technologies Canada Inc., Mississauga, ON). 
HEK293T cells were grown to ~70% confluency prior to transfection using Lipofectamine 2000 (Invitrogen 
Canada Inc., Burlington, ON). All plasmid construction and cDNA sequences were verified by sequencing.
Figure 6. Effects of PC1 on expression of Bcl-2 and Bax. (A) Expression of different proteins in control and PC1 
stable HEK293T cells after 48 hours of culture revealed by WB using different antibodies as indicated. β-actin 
served as loading controls. (B) Left panel, statistical data showing an averaged Bcl-2 level after normalization by 
β-actin (N = 5, P = 0.005, paired t-test). Right panel, data showing an averaged BAX level after normalization by 
β-actin (N = 5, P = 0.01, paired t-test).
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Co-IP. Protein extraction, immunoblotting and co-IP were performed as described previously33, 47, 48. Typically, 
20 and 200 mg of total cellular protein were used for immunoblotting and co-IP, respectively. HEK293T or HeLa 
cells were transiently transfected with pEGFP or pEGFP-PC1C for co-IP assays. At 40 hours post-transfection, 
cells were used for protein extraction and precipitation.
Cell surface biotinylation. Cell surface biotinylation was performed as previously with modifications46, 47. 
Briefly, HeLa cells transfected with GFP vector, GFP-PC1-5TMC, or GFP-PC1-1TMC, were grown to 90% conflu-
ency in 60 mm dishes. Cells were washed with ice-cold PBS then borate buffer (10 mM boric acid, 154 mM NaCl, 
7.2 mM KCl, 1.8 mM CaCl2, pH 9.0), and incubated with 1 mg/ml Pierce EZ-LinkTM Sulfo-NHS-SS-Biotin (Fisher 
Scientific Canada, Toronto, ON) at 4 °C with agitation for 30 minutes. After washing with quenching buffer (192 mM 
glycine, 25 mM Tris, pH 8.3), cells were lysed in ice-cold CelLyticTM-M reagent supplemented with protease inhibitor 
cocktail (Sigma-Aldrich Canada). The biotinylated and flow-through intracellular proteins were separated using 
100 µl of Pierce Avidin Agarose (Fisher Scientific Canada) by incubation overnight at 4 °C and subsequent centrifu-
gation. After intensive washing in NP40 buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP40) with protease inhibitor 
cocktail, biotinylated proteins were resuspended in 5 x SDS sample buffer and eluted from beads by heating at 65 °C 
for 5 minutes. An equal amount of biotinylated proteins and 20 µg of total and intracellular proteins were separated 
on 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) for immunoblotting.
Gene knockdown by siRNA. PKR siRNA (Santa Cruz, Cat#sc-36263) was used to transfect HEK293T cells 
using Lipofectamine 2000 reagent following the manufacturer’s instructions. The efficiency of the siRNA knock-
down was assessed by immunoblotting.
TUNEL assay. HEK293T cells were transfected with GFP or GFP-PC1-5TMC in 100 mm dishes. At 24 hours 
post-transfection, cells were split and grown on coverslips and subject to 2.5 µM of Tm treatment or GADD34 
transfection for 24 hours. Then cells were fixed with 2% paraformaldehyde for 10 minutes at room temperature 
and washed twice with PBS. Cells were then permeated with PBS containing 0.05% Triton X-100 for 3 minutes at 
room temperature, and subject to TUNEL assay using DeadEnd™ Colorimetric TUNEL System according to the 
manufacturer’s instructions (Promega North America, Madison, WI).
Data analysis. WB bands were quantified by Image J (National Institute of Health, Bethesda, MD) and 
data were expressed as mean ± SEM (N), analyzed and plotted using SigmaPlot 12 (Systat Software Inc., San 
Jose, CA), where SEM represents the standard error of the mean and N indicates the number of experimental 
repeats. A probability value (P) of less than 0.05 and 0.01 was considered significant (*) and very significant (**), 
respectively.
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